Thalidomide induces mucosal healing in Crohn's disease: Case report

World Journal of Gastroenterology

Volumn 17, Issue 45, 2011, Pages 5028-5031

  Leite, Márcio Rios ^a   Santos, Sandra Sousa ^b   Lyra, André Castro ^a   Mota, Jaciane ^b   Santana, Genoile Oliveira ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Monte Tabor Foundation   (Brazil)

Author keywords

Anti tumor necrosis factor alpha; Crohn's disease; Mucosal healing; Mycobacterium tuberculosis; Thalidomide

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE;

ADULT; ARTHRALGIA; ARTICLE; BLOODY DIARRHEA; CASE REPORT; COLONOSCOPY; COMPUTED TOMOGRAPHY SCANNER; CROHN DISEASE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EOSINOPHILIC GRANULOMA; FEVER; HUMAN; INFECTIOUS PNEUMONIA; LUNG NODULE; MALE; MYCOBACTERIUM TUBERCULOSIS; SCAR; TUBERCULOSIS;

EID: 83155168387     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i45.5028     Document Type: Article

References (20)

1. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 1991; 214: 230-238; discussion 238-240
2. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-305
3. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104
5. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-1811
6. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
7. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277
8. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278-1287
9. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892
10. Fu LM, Fu-Liu CS. Thalidomide and tuberculosis. Int J Tuberc Lung Dis 2002; 6: 569-572
11. Buonsenso D, Serranti D, Valentini P. Management of central nervous system tuberculosis in children: light and shade. Eur Rev Med Pharmacol Sci 2010; 14: 845-853
12. van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50 Suppl 3: III47-III53
13. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999; 58 Suppl 1: I107-I113
14. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445-1446
15. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17: 135-139
16. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50: 196-200
17. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-22387
18. Korzenik JR. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab. Gastroenterol Clin North Am 2004; 33: 285-301, ix
19. Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs 2001; 61: 777-787
20. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002; 35: 149-150